

Express Mail No.: EV452775444US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Borea et al.

Confirmation No.: 8955

Application No.:

10/600,116

Art Unit:

1614

Filed:

June 20, 2003

Examiner:

To be assigned

For:

ENHANCING TREATMENT OF MDR

Attorney Docket No.: 11201-505-999

CANCER WITH ADENOSINE A₃

Formerly: 58045-U1(46453)

ANTAGONISTS

TRANSMITTAL OF REVOCATION AND POWER OF ATTORNEY

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.36, Applicants submit herewith a Revocation and Power of Attorney executed by James R. Lattanzi, Chief Financial Officer of King Pharmaceuticals Research & Development, Inc., the assignee of the entire right, title and interest in, to and under the above-identified application.

Please direct all correspondence and telephone calls to Jones Day at the address indicated below. It is estimated that no fee is due in connection with this transmittal. In the event that a fee is required, please charge the required fee to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date: June 6, 2005

Thomas G. Rowan

ONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939



Express Mail No.: <u>EV452775444US</u> POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEMA	IN THE UNITED STATI	ESTATEM AN	DIKADEMAN	K OFF	ICE	
Application of:	Borea et al.		Confirmation	No.:	8955	
Serial No.:	10/600,116		Art Unit:	1614		
Filed:	June 20, 2003		Examiner:	To be a	ssigned	
For:	ENHANCING TREATMENT (WITH ADENOSINE A3 ANT				11201-505-999 58045-U1(46453)	
	REVOCATION	N AND POWER	OF ATTORNE	<u>Y</u>		
Commissioner P.O. Box 1450 Alexandria, VA					·	
Sir:						
King I and appoints:	Pharmaceuticals Research &	Development, Inc	. hereby revokes	any and	all previous powers	
☑ Practit	ctitioners at Customer Number 20583					
	/her/its/their attorney(s) or iness in the United States Pa					
Please	direct all correspondence ac	dress for the abov	e-identified appli	cation to:		
☐ The ab	ove mentioned Customer Nur	mber.				
⊠ Firm o	or Individual Name:					
Address:	Jones Day, 222 East 41st Street, New York, New York 10017					
Telephone:	hone: (212) 901-9028					
I am the:	Applicant/Inventor Assignee of record of the entire interest. See 37 CFR 3.71. (Statement under 37 CFR 3.73(b) is applicable)					
	SIGNATURE o	f Applicant or	Assignee of Re	cord		
Date:		Signature:	· · · · · · · · · · · · · · · · · · ·	···-		
	·	Typed Name:				
		Position/Title:	<u>.</u>			
	Stateme	ent Under 37 C.F	.R. 3.73(b)			
King Pharmac	teuticals Research & Devel- the assignee of the entire an assignee of less than t	right, title, and ir	iterest; or			

The extent (by, percentage) of its ownership interest is

%

in the patent application/patent identified above by virtue of either: \boxtimes An assignment from the inventor(s) of the patent application/patent identified above. The assignment in connection with U.S. application no. 10/600,116 was filed with the United States Patent and Trademark Office on January 27, 2005, a copy of which is attached hereto as Exhibit A. OR A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below: 1. From: To: The document was recorded in the United States Patent and Trademark Office on at Reel , Frame , or for which a copy thereof is attached. 2. From: To: The document was recorded in the United States Patent and Trademark Office on at Reel , Frame , or for which a copy thereof is attached. 3. From: To: The document was recorded in the United States Patent and Trademark Office on at Reel , Frame , or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. П Copies of assignments or other documents in the chain of title are attached. Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. ASSIGNEE: King Pharmaceuticals Research & Development, Inc. May 10, 2005 Date: Signature: Typed Name: Position/Title: Chief Financial Officer

Note: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required.

☐ Total of forms are submitted.

ASSIGNMENT

I/We, Pier Andrea BOREA, Pier Giovanni BARALDI, Shih-Fong CHEN, and Edward LEUNG for good and valuable consideration from King Pharmaceuticals Research and Development, Inc. having its principal place of business at CentreGreen Two, Suite 300, 4000 CentreGreen Way, Cary, North Carolina 27513, hereinafter called the Assignee, receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto the Assignee, its successors and assigns, the entire right, title and interest in, to and under an application for Letters Patent of the United States Serial No. 10/600,116, filed on June 20, 2003 for improvements in the ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A₃ ANTAGONISTS, priority rights ensuing therefrom, and the inventions and any of them therein set forth and described, and any and all Letters Patent of the United States and of countries foreign thereto which may be granted thereon or therefor, together with the right to apply for such Letters Patent.

And for the above consideration I/We agree promptly upon request of the Assignee, its successors or assigns, to execute and deliver without further compensation any power of attorney, assignment, application, whether original, divisional, continuation or reissue, or other papers which may be necessary or desirable fully to secure to the Assignee, its successors and assigns, the inventions and any of them described in said application and all patent rights therein, in the United States and in any country foreign thereto.

The undersigned agree(s) to furnish all pertinent facts and documents relating to said application, said invention and said patent(s) as may be known and accessible to the undersigned, and will testify as to the same in any interference or litigation related thereto, and will promptly execute and deliver to Assignee any and all papers, instruments or affidavits necessary or desirable to apply for, obtain, maintain or enforce said application or said patent(s) in connection with any interference which may be declared, and any litigation concerning this application or any continuation, division or reissue thereof or Patent(s) or reissue patent(s) issued thereon, and to cooperate with the

Assignee in every way possible in obtaining and producing evidence and proceeding with such interference or litigation.

The undersigned agree(s) to execute all papers and documents and to perform any act which may be necessary in connection with claims or provisions of the International Convention for the Protection of Industrial Property or similar agreements.

The undersigned agree(s) to perform all affirmative acts which may be necessary to obtain a grant of a valid United States patent(s) to the Assignee and to vest all rights therein hereby conveyed to said Assignee as fully and entirely as the same would have been held by the undersigned if this Assignment and sale had not been made.

The undersigned hereby authorize(s) and request(s) the Commissioner of Patents and Trademarks to issue any and all Letters Patent of the United States of America resulting from said application or any division or divisions or continuing or reissue applications thereof to the said Assignee, as Assignee of the entire interest, and hereby covenants that he or she has the full right to convey the entire interest herein assigned, and that he or she has not executed, and will not execute, any agreement in conflict herewith.

The undersigned hereby grant(s) EDWARDS & ANGELL, LLP of P.O. Box 55874, Boston, MA 02205, U.S.A. the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

In witness whereof, signed by the undersigned on the date(s) opposite the undersigned names.

Date: Sephenher ef 2001	Signature of Inventor:	Tier Anolus Bour			
ŕ	Name: Pier Andrea BOREA				
Witnessed by:					
Name: Austry So	ANDREA	BOVERO			
Date: 19/09/03					
		,			
Date: Seffenhu 19, 2003	Signature of Inventor: Name: Pier Giovanni B				
Witnessed by:					
Name: myfen Agha	redelity) MOJG	AN AGHAZADEH FABRIZ			
Date: 19/09/03	<i>V</i>				

BOS2_339357.1